Related Experiment Video
Updated: Dec 27, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Triglycerides and Cardiovascular Outcomes-Can We REDUCE-IT ?
Akshyaya Pradhan1, Monika Bhandari1, Pravesh Vishwakarma1
1Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Insights
High-dose omega-3 fatty acids show promise in reducing cardiovascular events, especially in patients with elevated triglycerides despite statin therapy. Further research confirms their potential role in managing residual cardiovascular risk.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- The relationship between triglycerides and coronary artery disease (CAD) remains debated.
- Triglyceride-lowering therapies, including fibrates, often show limited benefits for cardiovascular risk reduction when added to statins.
- A significant residual cardiovascular risk persists even with optimal low-density lipoprotein (LDL) cholesterol management.
Purpose of the Study:
- To evaluate the efficacy of high-dose omega-3 fatty acids in mitigating cardiovascular events.
- To assess the role of omega-3 fatty acids in managing residual cardiovascular risk in patients with hypertriglyceridemia.
- To clarify the controversial link between triglyceride levels and cardiovascular outcomes.
Main Methods:
- Review of recent large-scale clinical trials investigating high-dose omega-3 fatty acid supplementation.
- Analysis of cardiovascular outcomes in patient cohorts receiving omega-3s alongside LDL-lowering therapies.
- Examination of studies focusing on the triglyceride-lowering effects of omega-3 fatty acids.
Main Results:
- While older trials yielded mixed results, recent large trials with high-dose omega-3 fatty acids demonstrate promising cardiovascular benefits.
- Omega-3 fatty acids effectively reduce triglyceride levels.
- These benefits appear to be additive to the effects of statin therapy, addressing residual risk.
Conclusions:
- High-dose omega-3 fatty acids represent a potential therapeutic option for reducing cardiovascular events, particularly in patients with elevated triglycerides.
- They offer a strategy to manage residual cardiovascular risk that persists despite effective LDL cholesterol reduction.
- Further investigation into specific formulations and patient populations is warranted.
Abstract:
The causal linkage between triglycerides and coronary artery disease has been controversial. Most of the trials hitherto have shown marginal or no beneficial effects of reduction of triglycerides (with fibrates) on top of low-density lipoprotein (LDL) reduction. But a significant residual cardiovascular risk remains even after use of high dose of statins. Omega-3 fatty acids have been shown to reduce triglyceride levels and some old trials have shown the benefits of fish oils in reducing cardiovascular events. However, barring a few trials most of the large trials of omega-3 fatty acids are negative. Recently, few large trials have been conducted to see the effects of high dose omega-3 fatty acids on cardiovascular outcomes and some of them have shown promising results on top of LDL reduction.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipids: Dietary Sources and Requirements

